Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
In the present study, we tried to evaluate the ligands for Toll-like receptor 7 (TLR7) (R-848) and TLR 9 (CpG ODN) as adjuvants to augment the cellular and humoral immune responses as well as the generation of long-lasting immune memories following the vaccination with HBsAg in mice. The immune responses were assessed by enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISPOT), and fluorescence-activated cell sorter (FACS) at the total and at the single-cell levels. Our results showed that CpG ODN or R-848 could enhance HBsAg-specific humoral and cellular immune responses following boosts. When R-848 in combination with CpG was used as adjuvants, the immune responses to HBsAg were further strengthened. Additional analysis demonstrated that the majority of the long-lasting HBsAg-specific T cells displayed effector memory phenotype. Taken together, our results imply that CpG ODN and R-848 may be the candidates as adjuvants for use in prophylactic and therapeutic hepatitis B vaccine.
Ma
Rui
R
Department of Immunology, Zhongshan School of Medicne, Sun Yat-sen University, Guangzhou, People's Republic of China.
Du
Jia-li
JL
Huang
Jun
J
Wu
Chang-you
CY
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000917:Antibody Formation / Q000187:drug effects*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D004357:Drug Synergism; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D007093:Imidazoles / Q000494:pharmacology*; D007111:Immunity, Cellular / Q000187:drug effects*; D007117:Immunization, Secondary; D007156:Immunologic Memory / Q000187:drug effects; D007371:Interferon-gamma / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D014611:Vaccination
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; C408982:CPG-oligonucleotide; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D007093:Imidazoles; D009838:Oligodeoxyribonucleotides; D007371:Interferon-gamma; C402365:resiquimod